2,129 reports of this reaction
2.2% of all IPRATROPIUM BROMIDE reports
#7 most reported adverse reaction
FATIGUE is the #7 most commonly reported adverse reaction for IPRATROPIUM BROMIDE, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.. There are 2,129 FDA adverse event reports linking IPRATROPIUM BROMIDE to FATIGUE. This represents approximately 2.2% of all 98,863 adverse event reports for this drug.
Patients taking IPRATROPIUM BROMIDE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for IPRATROPIUM BROMIDE, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for IPRATROPIUM BROMIDE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 2,129 FDA reports for IPRATROPIUM BROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 2.2% of all adverse event reports for IPRATROPIUM BROMIDE, making it a notable side effect.
If you experience fatigue while taking IPRATROPIUM BROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.